Pramlintide

What Is Pramlintide?

Pramlintide (Symlin) is a synthetic analog of amylin — a 37-amino acid peptide hormone co-secreted with insulin from pancreatic beta cells. Amylin is deficient in type 1 diabetes (destroyed beta cells) and relatively deficient in type 2 diabetes. Pramlintide replaces this missing hormone, providing complementary metabolic effects to insulin.

Pramlintide works by slowing gastric emptying, suppressing post-meal glucagon secretion, and promoting satiety — all mechanisms that reduce post-meal glucose spikes. Unlike GLP-1 agonists, pramlintide does not stimulate insulin secretion; rather, it works alongside insulin to smooth out post-meal glucose excursions.

Pramlintide is the predecessor to the newer investigational amylin analogs like cagrilintide and amycretin. While cagrilintide offers longer-acting amylin agonism, pramlintide's FDA-approved status and established safety profile make it relevant.

What The Research Says

Clinical trials demonstrated pramlintide reduces HbA1c by 0.3-0.6% when added to insulin, reduces post-meal glucose excursions, and promotes modest weight loss (1-2 kg) — contrasting with insulin's weight-gaining effects. Phase 3 data supported FDA approval in 2005.

Real-world use has been limited by the requirement for pre-meal injections (3x daily), separate from insulin injections. This burden has limited adoption despite clinical efficacy. Fixed-ratio insulin/pramlintide combinations have been explored but not commercialized.

📚 Key Reference: PMID: 15277946 (pramlintide type 2 diabetes)

Common Uses

• Type 1 diabetes (FDA-approved, adjunct to insulin)
• Type 2 diabetes (FDA-approved, adjunct to insulin)
• Post-meal glucose control
• Appetite reduction in diabetics

Important Safety Information

Hypoglycemia risk is the primary concern — pramlintide combined with insulin requires insulin dose reduction (typically 50%) at initiation. Nausea is common during titration. Injection site reactions. Not for use in patients with gastroparesis. Consult your provider.

Questions To Ask Your Provider

1. How will my insulin dose be adjusted when starting pramlintide?
2. What is the meal-time injection schedule?
3. What hypoglycemia management plan is in place?

Regulatory Status

FDA-approved as Symlin (AstraZeneca/Amylin Pharmaceuticals, 2005) for type 1 and type 2 diabetes as adjunct to insulin. Currently marketed by AstraZeneca.